This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Murphy, M. B. Articles by Goldberg, L. I. Search for Related Content PubMed PubMed Citation Articles by Murphy, M. B. Articles by Goldberg, L. I. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information High Blood Pressure Hazardous Substances DB POTASSIUM SODIUM

Circulation, Vol 76, 1312-1318, Copyright © 1987 by American Heart Association

ARTICLES

Augmentation of renal blood flow and sodium excretion in hypertensive patients during blood pressure reduction by intravenous administration of the dopamine1 agonist fenoldopam

MB Murphy, CE McCoy, RR Weber, ED Frederickson, FL Douglas and LI Goldberg
Department of Pharmacological and Physiological Sciences, University of Chicago, IL 60637.

Activation of dopamine1 (DA1) receptors relaxes vascular smooth muscle, especially in the renal vascular bed. Fenoldopam, the first selective DA1-receptor agonist that can be administered to man, was infused intravenously in 17 patients with essential hypertension (mean blood pressure 152/101 mm Hg). It reduced blood pressure in a dose-dependent fashion at doses between 0.025 and 0.5 microgram/kg/min and the antihypertensive effect was sustained during 2 hr infusions. In 10 patients studied during free-water diuresis, fenoldopam increased renal plasma flow by 42%, glomerular filtration rate by 6%, and sodium excretion by 202%, while lowering mean arterial pressure by 12% (all p less than .05). Similar promotion of sodium excretion was observed during blood pressure reduction in six additional patients studied without water loading. Pronounced enhancement of renal function in spite of blood pressure reduction suggests that fenoldopam might have a special role in the treatment of patients with hypertension and renal impairment.

This article has been cited by other articles:

				T. Bove, G. Landoni, M. Grazia Calabro, G. Aletti, G. Marino, E. Cerchierini, G. Crescenzi, and A. Zangrillo Renoprotective Action of Fenoldopam in High-Risk Patients Undergoing Cardiac Surgery: A Prospective, Double-Blind, Randomized Clinical Trial Circulation, June 21, 2005; 111(24): 3230 - 3235. [Abstract] [Full Text] [PDF]

				S. D. Weisbord and P. M. Palevsky Radiocontrast-Induced Acute Renal Failure J Intensive Care Med, March 1, 2005; 20(2): 63 - 75. [Abstract] [PDF]

				J. N. Ghansah and J. T. Murphy Complications of Major Aortic and Lower Extremity Vascular Surgery Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2004; 8(4): 335 - 361. [Abstract] [PDF]

				A. Morelli, M. Rocco, G. Conti, A. Orecchioni, R. Alberto De Blasi, F. Coluzzi, and P. Pietropaoli Monitoring Renal Oxygen Supply in Critically-Ill Patients Using Urinary Oxygen Tension Anesth. Analg., December 1, 2003; 97(6): 1764 - 1768. [Abstract] [Full Text] [PDF]

				G. W. Stone, P. A. McCullough, J. A. Tumlin, N. E. Lepor, H. Madyoon, P. Murray, A. Wang, A. A. Chu, G. L. Schaer, M. Stevens, et al. Fenoldopam Mesylate for the Prevention of Contrast-Induced Nephropathy: A Randomized Controlled Trial JAMA, November 5, 2003; 290(17): 2284 - 2291. [Abstract] [Full Text] [PDF]

				M. B. Murphy, C. Murray, and G. D. Shorten Fenoldopam -- A Selective Peripheral Dopamine-Receptor Agonist for the Treatment of Severe Hypertension N. Engl. J. Med., November 22, 2001; 345(21): 1548 - 1557. [Full Text] [PDF]

				C. M. Sehgal, P. H. Arger, A. C. Silver, J. A. Patton, H. M. Saunders, A. Bhattacharyya, and C. P. Bell Renal Blood Flow Changes Induced with Endothelin-1 and Fenoldopam Mesylate at Quantitative Doppler US: Initial Results in a Canine Study Radiology, May 1, 2001; 219(2): 419 - 426. [Abstract] [Full Text]

				J. G. Ramsay Cardiac Management in the ICU Chest, May 1, 1999; 115(suppl_2): 138S - 144S. [Abstract] [Full Text] [PDF]

				T. Hussain and M. F. Lokhandwala Renal Dopamine Receptor Function in Hypertension Hypertension, August 1, 1998; 32(2): 187 - 197. [Abstract] [Full Text] [PDF]

				I. Saito, H. Kawabe, C. Hasegawa, Y. Iwaida, H. Yamakawa, T. Saruta, E. Takeshita, S. Nagano, and T. Sekihara Effect of L-dopa in Young Patients with Hypertension Angiology, September 1, 1991; 42(9): 691 - 695. [Abstract] [PDF]